Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update.

× No keyword cloud information.

4 in total

1. Activation of the vitamin D receptor transcription factor stimulates the growth of definitive erythroid progenitors.

Authors: Jeffrey Barminko; Brad M Reinholt; Alexander Emmanuelli; Alannah N Lejeune; Margaret H Baron
Journal: Blood Adv Date: 2018-06-12

2. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.

Authors: Jean-Emmanuel Kurtz; Pierre Soubeyran; Mauricette Michallet; Elisabeth Luporsi; Hélène Albrand
Journal: Onco Targets Ther Date: 2016-10-28 Impact factor: 4.147

3. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.

Authors: Mauricette Michallet; Elisabeth Luporsi; Pierre Soubeyran; Nadia Ali Amar; Vincent Boulanger; Miguel Carreiro; Louis-Marie Dourthe; Jean-Luc Labourey; Daniel Lepille; Frédéric Maloisel; Jean-Loup Mouysset; Sophie Nahon; Bérengère Narciso; Pierre Nouyrigat; Raouf Radji; Nacéra Sakek; Hélène Albrand
Journal: BMC Cancer Date: 2014-07-10 Impact factor: 4.430

4. Biosimilar Retacrit^® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.

Authors: Christoph Losem; Michael Koenigsmann; Christine Rudolph
Journal: Onco Targets Ther Date: 2017-02-28 Impact factor: 4.147

4 in total

Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update.

1. Activation of the vitamin D receptor transcription factor stimulates the growth of definitive erythroid progenitors.

2. Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients.

3. BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study.

4. Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.

4. Biosimilar Retacrit^® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study.